FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound The U.S. Food and Drug Administration (FDA) has ordered Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday. Reuters Reuters

...

Pfizer is "working with the FDA to finalize a protocol to study patients who may be in need of retreatment," and will provide details when available, a company spokesperson said.